Table of Content

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines


2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Long Acting Drug Delivery
3.2.1. Types of Long Acting Drug Delivery Systems
3.3. Long Acting Drug Delivery Technologies
3.3.1. Underlying Principle
3.3.2. Associated Strategies
3.4. Concluding Remarks

4. TECHNOLOGY LANDSCAPE
4.1. Chapter Overview
4.2. Long Acting Drug Delivery: Technology Landscape
4.2.1. Analysis by Principle
4.2.2. Analysis by Strategy
4.2.3. Analysis by Type of Material Used
4.2.4. Analysis by Compatible Dosage Form(s)
4.2.5. Analysis by Extended Dosing Interval(s)
4.2.6. Analysis by Type of Molecule(s) Delivered
4.2.7. Analysis by Highest Phase of Development
4.2.8. Analysis by Number of Approved Drugs
4.2.9. Analysis by Therapeutic Area(s)
4.3. Long Acting Drug Delivery: Technology Developers Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Technologies

5. SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Long Acting Drug Delivery: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Location of Facilities
5.2.6. Analysis by Type of Service Provider(s)
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Compatible Dosage Form(s)
5.2.9. Analysis by Scale of Operation and Compatible Dosage Form(s)
5.2.10. Analysis by Service(s) Offered
5.2.11. Analysis by Company Size and Service(s) Offered
5.2.12. Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
5.2.13. Analysis by Type of Molecule(s) Supported
5.2.14. Analysis by Type of Service Provider(s) and Type of Molecule(s) Supported

6. TECHNOLOGY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Technology Competitiveness Analysis
6.4.1. Long Acting Drug Delivery Technologies offered by Small Companies
6.4.2. Long Acting Drug Delivery Technologies offered by Mid-sized Companies
6.4.3. Long Acting Drug Delivery Technologies offered by Large Companies
6.4.4. Long Acting Drug Delivery Technologies offered by Very Large Companies

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis
7.4.1. Long Acting Drug Delivery Service Providers based in North America
7.4.2. Long Acting Drug Delivery Service Providers based in Europe
7.4.3. Long Acting Drug Delivery Service Providers based in Asia-Pacific

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Adare Pharma Solutions
8.2.1. Company Overview
8.2.2. Technology Portfolio
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. AMW
8.3.1. Company Overview
8.3.2. Technology Portfolio
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. Bostal Drug Delivery
8.4.1. Company Overview
8.4.2. Technology Portfolio
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Creative Biolabs
8.5.1. Company Overview
8.5.2. Technology Portfolio
8.5.3. Service Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. ForDoz Pharma
8.6.1. Company Overview
8.6.2. Technology Portfolio
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. InnoCore Pharmaceuticals
8.7.1. Company Overview
8.7.2. Technology Portfolio
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Integral BioSystems
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook
8.9. LATITUDE Pharmaceuticals
8.9.1. Company Overview
8.9.2. Technology Portfolio
8.9.3. Service Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Navin Saxena Research and Technology Centre (NSRT)
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Service Portfolio
8.10.4. Recent Developments and Future Outlook
8.11. Samyang Biopharm
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Service Portfolio
8.11.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Long Acting Drug Delivery Technologies and Services: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. Local and International Deals

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Long Acting Drug Delivery: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Most Popular Keywords
10.3.4. Most Popular Journals: Analysis by Number of Publications
10.3.5. Most Popular Publishers: Analysis by Number of Publications
10.3.6. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.7. Key Funding Institutes: Analysis by Number of Publications

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Long Acting Drug Delivery: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Type of Patent and Publication Year
11.3.3. Analysis by Geography
11.3.4. Analysis by CPC Symbols
11.3.5. Leading Industry Players: Analysis by Number of Patents
11.3.6. Analysis by Type of Organization
11.4. Patent Benchmark Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Patent Valuation Analysis

12. GRANT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Long Acting Drug Delivery: Grant Analysis
12.3.1. Analysis by Year of Grant Award
12.3.2. Analysis by Amount Awarded
12.3.3. Analysis by Support Period
12.3.4. Analysis by Support Period and Funding Institute Center
12.3.5. Analysis by Type of Grant Application
12.3.6. Analysis by Purpose of Grant Award
12.3.7. Analysis By Activity Code
12.3.8. Analysis by NIH Spending Category
12.3.9. Analysis by Study Section Involved
12.3.10. Popular NIH Departments: Analysis by Number of Grants
12.3.11. Analysis by Type of Recipient Organization
12.3.12. Prominent Program Officers: Analysis by Number of Grants
12.3.13. Popular Recipient Organizations: Analysis by Number of Grants
12.3.14. Popular Recipient Organizations: Analysis by Grant Amount
12.3.15. Analysis by Region of Recipient Organizations
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Long Acting Drug Delivery Technologies Market, 2023-2035
13.3.1. Long Acting Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed
13.3.1.1. Long Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035
13.3.1.2. Long Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035
13.3.2. Long Acting Drug Delivery Technologies Market: Analysis by Principle
13.3.2.1. Long Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035
13.3.2.2. Long Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035
13.3.3. Long Acting Drug Delivery Technologies Market: Analysis by Strategy
13.3.3.1. Long Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035
13.3.3.2. Long Acting Drug Delivery Technologies Market for Long Acting Implants, 2023-2035
13.3.3.3. Long Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
13.3.3.4. Long Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035
13.3.3.5. Long Acting Drug Delivery Technologies Market for Long Acting Hydrogels, 2023-2035
13.3.3.6. Long Acting Drug Delivery Technologies Market for Long Acting Microneedles, 2023-2035
13.3.3.7. Long Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035
13.3.3.8. Long Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035
13.3.4. Long Acting Drug Delivery Technologies Market: Analysis by Compatible Dosage Form
13.3.4.1. Long Acting Drug Delivery Technologies Market for Injectables, 2023-2035
13.3.4.2. Long Acting Drug Delivery Technologies Market for Implantables, 2023-2035
13.3.4.3. Long Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035
13.3.4.4. Long Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035
13.3.4.5. Long Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035
13.3.4.6. Long Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035
13.3.5. Long Acting Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered
13.3.5.1. Long Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035
13.3.5.2. Long Acting Drug Delivery Technologies Market for Biologics, 2023-2035
13.3.5.3. Long Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035
13.3.6. Long Acting Drug Delivery Technologies Market: Analysis by Type of Material Used
13.3.6.1. Long Acting Drug Delivery Technologies Market for Polymer-based, 2023-2035
13.3.6.2. Long Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035
13.3.7. Long Acting Drug Delivery Technologies Market: Analysis by Region
13.3.7.1. Long Acting Drug Delivery Technologies Market in North America, 2023-2035
13.3.7.2. Long Acting Drug Delivery Technologies Market in Europe, 2023-2035
13.3.7.3. Long Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035
13.3.7.4. Long Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035
13.4. Global Long Acting Drug Delivery Services Market, 2023-2035
13.4.1. Long Acting Drug Delivery Services Market: Analysis by Compatible Dosage Form
13.4.1.1. Long Acting Drug Delivery Services Market for Injectables, 2023-2035
13.4.1.2. Long Acting Drug Delivery Services Market for Implantables, 2023-2035
13.4.1.3. Long Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
13.4.1.4. Long Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
13.4.1.5. Long Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
13.4.1.6. Long Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
13.4.2. Long Acting Drug Delivery Services Market: Analysis by Type of Molecule Supported
13.4.2.1. Long Acting Drug Delivery Services Market for Small Molecules, 2023-2035
13.4.2.2. Long Acting Drug Delivery Services Market for Biologics, 2023-2035
13.4.2.3. Long Acting Drug Delivery Services Market for Other Molecules, 2023-2035
13.4.3. Long Acting Drug Delivery Services Market: Analysis by Region
13.4.3.1. Long Acting Drug Delivery Services Market in North America, 2023-2035
13.4.3.2. Long Acting Drug Delivery Services Market in Europe, 2023-2035
13.4.3.3. Long Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035

14. CONCLUSION

15. INTERVIEW TRANSCRIPTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS